NEW YORK - Arima Genomics said on Tuesday it has fetched $7 million in a Series B financing round.
The San Diego-based 3D genomics company said it will use the funds to expand its product portfolio and bioinformatics capabilities to "serve a broader spectrum of scientific and translational medicine applications." Additionally, the company will also use the money to ramp up its operational and commercial capacity worldwide.
New investors in this round include Genetron Health, Tech Coast Angels, Ladder Ventures, and Hiaqua Investments, joined by existing investors Agilent Technologies, Co-win Ventures, Vectr Ventures, and Berkeley Catalyst Fund.
"Arima Genomics' relationship with its more than 600 global customers is a testament to both its humble, science-led culture and the applicability of its product portfolio in driving discovery in critical clinical research programs," said Genetron Health CSO Hai Yan in a statement.
According to Arima CEO and Cofounder Siddarth Selvaraj, the company's 3D genomics technology has helped its customers publish more than 200 peer-reviewed studies to date, spanning the fields of cancer, neurobiology, immunology, and other complex diseases.